Shandong Buchang Pharmaceuticals Co Ltd
SSE:603858
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
13.99
20.02
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Shandong Buchang Pharmaceuticals Co Ltd
Revenue
Shandong Buchang Pharmaceuticals Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Shandong Buchang Pharmaceuticals Co Ltd
SSE:603858
|
Revenue
ÂĄ11B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Revenue
ÂĄ13.2B
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Revenue
ÂĄ9.8B
|
CAGR 3-Years
5%
|
CAGR 5-Years
9%
|
CAGR 10-Years
19%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Revenue
ÂĄ31B
|
CAGR 3-Years
13%
|
CAGR 5-Years
4%
|
CAGR 10-Years
13%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Revenue
ÂĄ40.8B
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Revenue
ÂĄ5.8B
|
CAGR 3-Years
94%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
Shandong Buchang Pharmaceuticals Co Ltd
Glance View
Shandong Buchang Pharmaceuticals Co Ltd, a stalwart in China's pharmaceutical industry, was founded with a traditional focus but a modern vision. The company thrives on its deep expertise in developing and manufacturing traditional Chinese medicine (TCM) products, capitalizing on the rich tapestry of Eastern medicinal practices. Its extensive portfolio spans cardiovascular, cerebrovascular, and neurological disorders, areas highly pertinent to China’s aging population. By seamlessly integrating modern scientific techniques with age-old herbal wisdom, Buchang positions itself uniquely in a market that appreciates both tradition and innovation. This dual focus allows the company to tap into the growing demand for health solutions that marry efficacy with cultural familiarity. Financially, Buchang Pharmaceuticals' revenue is primarily fueled by its established healthcare products, which are marketed extensively across China’s vast healthcare network. The company shrewdly invests in building dedicated sales channels, leveraging a combination of direct engagement with healthcare professionals and strategic partnerships with medical institutions. Their emphasis on R&D ensures a steady pipeline of products, aiming to break into new therapeutic areas and expand its market presence. Buchang’s strategy to blend traditional remedies with modern delivery forms not only bolsters its domestic sales but also paves the way for potential international expansion, as global interest in holistic and alternative health solutions continues to grow. This sophisticated operational model underscores Buchang's ability to adapt and prosper amid shifting healthcare paradigms.
See Also
What is Shandong Buchang Pharmaceuticals Co Ltd's Revenue?
Revenue
11B
CNY
Based on the financial report for Sep 30, 2025, Shandong Buchang Pharmaceuticals Co Ltd's Revenue amounts to 11B CNY.
What is Shandong Buchang Pharmaceuticals Co Ltd's Revenue growth rate?
Revenue CAGR 5Y
-6%
Over the last year, the Revenue growth was -7%. The average annual Revenue growth rates for Shandong Buchang Pharmaceuticals Co Ltd have been -11% over the past three years , -6% over the past five years .